Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and confirmed clinical site readiness to start a Phase 2a trial for Nu-3, a treatment for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy, building on positive preclinical data. The company focuses on addressing antibiotic-resistant bacterial infections with its Bisphosphocin® class of antimicrobials.
How this was made
The 30-second read
Why it matters
The approval removes a regulatory hurdle, allowing the company to generate clinical data that could de‑risk the program and attract partners.
Market read
First regulatory clearance for Nu-3; may trigger short‑term buying interest in LABT.
What to watch
Funding runway and competition from other antimicrobial platforms.
Background
Press release announcing first‑in‑human trial readiness for a novel topical antimicrobial gel.
Ticker impact
Lakewood-Amedex Biotherapeutics received IRB approval and site readiness to start its Phase 2a trial of Nu-3 for infected diabetic foot ulcers.
Potential short‑term upside of 5‑10% if trial proceeds on schedule.
IRB clearance is a key step for biotech timelines; investors often reward such news.
Market effects
May lift sentiment for antimicrobial biotech peers.
Limited to US biotech sector.
Modest; adds to global antimicrobial innovation narrative.
Counterpoint
Trial could face enrollment delays or safety issues, limiting upside.
Key entities
- CompanyLakewood-Amedex Biotherapeutics Inc.
Clinical‑stage biotech developing Bisphosphocin® antimicrobials.
- IndividualDr. David G. Armstrong
Study chair and expert in diabetic foot ulcer care.
